TransMedics Group, Inc. (TMDX)

NGM – Real vaqt narxi. Valyuta: USD

68.44

-9.31 (-11.97%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

69.70

+1.26 (1.84%)

Bozordan keyin: Jun 26, 2026, 7:55 PM EDT

12.06.2026

Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP Investments

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating TransMedics Group, Inc. (NASDAQ: TMDX) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws.

09.06.2026

TransMedics: Why I'm Still Bullish After The Collapse

TransMedics (TMDX) faces decelerating revenue growth, margin pressure, and increased investment, yet maintains strong market share gains and competitive positioning. TMDX's logistics and clinical services now comprise nearly 40% of revenue, enhancing competitive advantages and supporting long-term margin strength. Despite growth normalizing to 20-25% and compressed margins, I see current valuation at 4x EV/Sales as attractive, supporting a Buy rating.

04.06.2026

TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?

TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?

02.06.2026

This Healthcare Infrastructure Stock Is Risky, But the Upside Looks Huge

TransMedics (TMDX +1.19%) has been hit hard as investors question margins, spending, and execution. But beneath the sell-off, the company's Organ Care System, aviation network, and National OCS Program could be building a deeper transplant infrastructure moat than the market realizes.

28.05.2026

Reasons to Retain TransMedics Stock in Your Portfolio for Now

TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.

25.05.2026

TransMedics: Despite Earnings Miss, Growth Story Remains Intact

TransMedics remains a 'Strong Buy' despite a 50% stock decline and Q1 2026 earnings miss, supported by robust long-term growth initiatives. TMDX's portfolio expansion includes CHOPS as a complementary offering and aggressive European NOP rollout, aiming to expand its addressable market. Q1 2026 revenue grew 21% year-over-year to $174 million, led by liver segment strength, though higher costs compressed margins and net income.

21.05.2026

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANDOVER, Mass., May 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 19, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 37,367 shares of its common stock and an aggregate of 24,848 restricted stock units to 14 employees, each as a material inducement for each employee's entry into employment with TransMedics.

Videolar

No Data

There is no data to display

Press-relizlar

12.06.2026

Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP Investments

21.05.2026

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

05.05.2026

TransMedics Reports First Quarter 2026 Financial Results

ANDOVER, Mass., May 5, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2026.

29.04.2026

TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH

Proposed strategic investment in Germany-based PAD Aviation, a premier European private aviation operator, intended to lay the foundation for TransMedics to establish a dedicated organ transplantation air logistics network across Europe ANDOVER, Mass., April 29, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that it has entered into a definitive agreement to invest in PAD Aviation, a premier Germany-based private aviation operator.

TransMedics Group, Inc. (TMDX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

TransMedics Group, Inc. (TMDX)

Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP Investments

TransMedics: Why I'm Still Bullish After The Collapse

TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?

This Healthcare Infrastructure Stock Is Risky, But the Upside Looks Huge

Reasons to Retain TransMedics Stock in Your Portfolio for Now

TransMedics: Despite Earnings Miss, Growth Story Remains Intact

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP Investments

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Reports First Quarter 2026 Financial Results

TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH

Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP Investments

TransMedics: Why I'm Still Bullish After The Collapse

TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?

This Healthcare Infrastructure Stock Is Risky, But the Upside Looks Huge

Reasons to Retain TransMedics Stock in Your Portfolio for Now

TransMedics: Despite Earnings Miss, Growth Story Remains Intact

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP Investments

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Reports First Quarter 2026 Financial Results

TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH

Search stocks

TransMedics Group, Inc. (TMDX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

TransMedics Group, Inc. (TMDX)

Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP Investments

TransMedics: Why I'm Still Bullish After The Collapse

TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?

This Healthcare Infrastructure Stock Is Risky, But the Upside Looks Huge

Reasons to Retain TransMedics Stock in Your Portfolio for Now

TransMedics: Despite Earnings Miss, Growth Story Remains Intact

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP Investments

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Reports First Quarter 2026 Financial Results

TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH

Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP Investments

TransMedics: Why I'm Still Bullish After The Collapse

TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?

This Healthcare Infrastructure Stock Is Risky, But the Upside Looks Huge

Reasons to Retain TransMedics Stock in Your Portfolio for Now

TransMedics: Despite Earnings Miss, Growth Story Remains Intact

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Videolar

No Data

Press-relizlar

Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP Investments

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Reports First Quarter 2026 Financial Results

TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH